AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) A method for the therapeutic treatment of cancer slowing the progression of a tumor in an animal, which method comprises administering to an animal having a cancer tumor due to a genetic defect in the p53 gene a nitroxide compound of Formula I or a prodrug thereof in an amount sufficient to slow the progression of the tumor treat said cancer, wherein said cancer tumor is susceptible to treatment by said nitroxide compound of Formula I or prodrug thereof, and wherein said nitroxide or prodrug thereof is a compound of Formula I or II is defined as:

$$R_{9}$$
 R_{10}
 R_{11}
 R_{5}
 R_{1}
 R_{2}
 R_{10}
 R_{10}
 R_{11}
 R_{2}
 R_{10}
 R_{11}
 R_{2}
 R_{10}
 R_{11}
 R_{2}
 R_{1}

Formula I or Formula II

wherein R_1 is selected from the group consisting of H, OH, OZ, O·, and =O-and Y, wherein Y is a leaving group, which can be converted to H, OH, O· or =O by reaction with a nucleophilic agent, and Z is selected from the group consisting of a C_{1-20} C_{1-6} aliphatic group, a monocyclic aromatic group, a bicyclic aromatic group, a multicyclic aromatic group, a C_{1-20} C_{1-10} alicyclic group, a noncarbon/nonoxygen moiety, a carbohydrate, a lipid, a nucleic acid and a protein, wherein R_2 , R_3 , R_4 and R_5 are independently selected from the group consisting of a C_{1-20} C_{1-6} alkyl group, a C_{2-20} C_{2-6} alkenyl group, a C_{2-20} C_{2-6} alkynyl group, and -CH₂-[CR' R"]_m-CH₃, wherein R' is selected from the group consisting of hydrogen, a C_{1-20} C_{1-6} aliphatic group, and a monocyclic aromatic group, a bicyclic aromatic group, and a multicyclic aromatic group, a bicyclic aromatic group, a multicyclic aromatic group, a monocyclic aromatic group, a bicyclic aromatic group, a multicyclic aromatic group, a carbohydrate, a lipid, a nucleic acid, and a protein,

 $m \le 4$ 30, and R_2 and R_3 or R_4 and R_5 can be connected through one or more members, each of which is independently selected from the group consisting of carbon and a heteroatom, wherein R_6 , R_7 , R_8 and R_9 are independently selected from the group consisting

of hydrogen, a hydroxyl group, a C_{1-20} C_{1-6} aldehydic group, a C_{1-20} C_{3-6} keto group, a primary amino group, a secondary amino group, a tertiary amino group, a sulfido group, a disulfido group, a sulfato group, a sulfito group, a sulfonato group, a sulfinato group, a sulfenato group, a sulfamato group, a metal containing group, a silicone group, a halide, a C_L 20 C₁₋₆ ester-containing group, a carboxyl group, a phosphato group, a phosphino group, a phosphinato group, a phosphonato group, a C_{1-20} C_{1-6} alkyl group, a C_{2-20} C_{2-6} alkenyl group, a C₂₋₂₀ C₂₋₆ alkynyl group, and -CH₂-[CR' R"]_m-CH₃, wherein R' is selected from the group consisting of hydrogen, a C_{1-20} C_{1-6} aliphatic group, and a monocyclic aromatic group, a bicyclic aromatic group, and a multicyclic aromatic group, and R" is selected from the group consisting of hydrogen, a C_{1-20} C_{1-6} aliphatic group, a monocyclic aromatic group, a bicyclic aromatic group, a multicyclic aromatic group, a C₁₋₂₀ C₅₋₁₀ alicyclic group, a noncarbon/nonoxygen moiety, a carbohydrate, a lipid, a nucleic acid and a protein, and $m \le \underline{4}$ 30, and wherein any one of R₆, R₇, R₈ and R₉ can be attached covalently or noncovalently to a polymer of synthetic or natural origin, wherein in Formula I, one of R₆ and R₇ and one of R₈ and R₉ can be absent such that a double bond joins the two carbon atoms to which the remaining R groups are attached, wherein n = 0-4 20 in Formula I, and n = 1-20 in Formula H, wherein X is a heteroatom, and wherein R_{10} and R_{11} are independently selected from the group consisting of a C_{1-20} C_{1-6} aliphatic group, a monocyclic aromatic group, a bicyclic aromatic group, a multicyclic aromatic group, a C₁₋₂₀ aliphatic/aromatic group, a heteroatomic group, a C_{1-20} C_{1-6} ether-containing group, a C_{1-20} C_{3-6} keto group, a C_{1-20} C_{1-6} aldehydic group, a carboxamido group, a cyano group, an amino group, and a carboxyl group, a selenium-containing group, a sulfato group, a sulfito group, a sulfenato group, a sulfinate group, and a sulfenate group, and wherein R₁₀ and R₁₁ can be connected through an aliphatic group and/or an aromatic group, or R₁₀ and/or R₁₁ can comprise a member selected from the group consisting of a carbohydrate, a lipid, a nucleic acid and a protein.

2-3. (Canceled)

- 4. (Withdrawn) The method of claim 1, wherein said aliphatic group is branched, substituted and/or unsaturated.
- 5. (Withdrawn) The method of claim 4, wherein said aliphatic group is substituted with a member selected from the group consisting of oxygen, phosphorus, selenium, sulfur and nitrogen.

- 6. (Withdrawn) The method of claim 1, wherein said aromatic group comprises a five- or six-membered ring, in which each of the five or six members is independently selected from the group consisting of carbon and a heteroatom.
- 7. (Withdrawn) The method of claim 6, wherein said heteroatom is selected from the group consisting of nitrogen, oxygen, sulfur, phosphorus and boron.
 - 8. (Canceled)
 - 9. (Withdrawn) The method of claim 6, wherein said aromatic group is substituted.
- 10. (Withdrawn) The method of claim 9, wherein said aromatic group is substituted with a heteroatom.
- 11. (Withdrawn) The method of claim 10, wherein said heteroatom is selected from the group consisting of nitrogen, oxygen, sulfur, phosphorus and boron.
- 12. (Withdrawn) The method of claim 1, wherein said alicyclic group is substituted and/or unsaturated.
- 13. (Withdrawn) The method of claim 11, wherein said alicyclic group is substituted with a heteroatom.
 - 14. (Withdrawn) The method of claim 1, wherein said amino group is substituted.
- 15. (Withdrawn) The method of claim 14, wherein said amino group is substituted with up to three substituents selected from the group consisting of a C_{1-20} aliphatic group, a monocyclic aromatic group, a bicyclic aromatic group, a multicyclic aromatic group, and a C_{1-20} alicyclic group.
- 16. (Withdrawn) The method of claim 15, wherein said aromatic group comprises a five- or six-membered ring, in which each of the five or six members is independently selected from the group consisting of carbon and a heteroatom.
- 17. (Withdrawn) The method of claim 16, wherein said heteroatom is selected from the group consisting of nitrogen, oxygen, sulfur, phosphorus and boron.

- 18. (Withdrawn) The method of claim 15, wherein said aromatic group is substituted.
- 19. (Withdrawn) The method of claim 18, wherein said aromatic group is substituted with a heteroatom.
- 20. (Withdrawn) The method of claim 19, wherein said heteroatom is selected from the group consisting of nitrogen, oxygen, sulfur, phosphorus and boron.

$$21. - 27.$$
 (Canceled)

28. (Currently Amended) A method for <u>delaying the onset of tumor formation or slowing the progression of a tumor</u> the prophylactic or therapeutic treatment of cancer in an animal, which method comprises administering to an animal at risk for developing a cancer tumor or having a cancer tumor due to ataxia telangicatasia or Li Fraumeni syndrome a compound of Formula I nitroxide or a prodrug thereof in an amount sufficient to <u>delay the onset or slow the progression of the tumor prevent or treat said cancer</u>, wherein said cancer tumor is susceptible to prevention or treatment treatment by said nitroxide compound of Formula I or prodrug thereof, and wherein said nitroxide or prodrug thereof is a compound of Formula I is defined as or II:

Formula I or Formula II

wherein R_1 is selected from the group consisting of H, OH, OZ, O·, and =O and Y, wherein Y is a leaving group, which can be converted to H, OH, O· or =O by reaction with a nucleophilic agent, and Z is selected from the group consisting of a C_{1-20} aliphatic group, a monocyclic aromatic group, a bieyclic aromatic group, a multicyclic aromatic group, a C_{5-10} alicyclic group, a noncarbon/nonoxygen moiety, a carbohydrate, a lipid, a nucleic acid and a protein, wherein R_2 , R_3 , R_4 and R_5 are independently selected from the group consisting of a C_{1-20} C_{1-6} alkyl group, a C_{2-20} C_{2-6} alkenyl group, a C_{2-20} C_{2-6} alkynyl group, and -CH₂-[CR' R"]_m-CH₃, wherein R' is selected from the group consisting of hydrogen, a C_{1-20} C_{1-6} aliphatic group, and a monocyclic aromatic group, a bieyelic aromatic group, and a

multicyclic aromatic group, and R" is selected from the group consisting of hydrogen, a C_{1-20} C_{1-6} aliphatic group, and a monocyclic aromatic group, a bicyclic aromatic group, a multicyclic aromatic group, a C_{1-20} C_{5-10} alicyclic group, a noncarbon/nonoxygen moiety, a carbohydrate, a lipid, a nucleic acid, and a protein,

 $m \le 4.30$, and R_2 and R_3 or R_4 and R_5 can be connected through one or more members, each of which is independently selected from the group consisting of carbon and a heteroatom, wherein R₆, R₇, R₈ and R₉ are independently selected from the group consisting of hydrogen, a hydroxyl group, a C_{1-20} C_{1-6} aldehydic group, a C_{1-20} C_{3-6} keto group, a primary amino group, a secondary amino group, a tertiary amino group, a sulfido group, a disulfido group, a sulfato group, a sulfito group, a sulfonato group, a sulfinato group, a sulfenato group, a sulfamato group, a metal-containing group, a silicone group, a halide, a C_{1-20} C_{1-6} estercontaining group, a carboxyl group, a phosphato group, a phosphino group, a phosphinato group, a phosphonato group, a C_{1-20} C_{1-6} alkyl group, a C_{2-20} C_{2-6} alkenyl group, a C_{2-20} C_{2-6} alkynyl group, and -CH₂-[CR' R"]_m-CH₃, wherein R' is selected from the group consisting of hydrogen, a C_{1-20} C_{1-6} aliphatic group, and a monocyclic aromatic group, a bicyclic aromatic group, and a multicyclic aromatic group, and R" is selected from the group consisting of hydrogen, a C_{1-20} C_{1-6} aliphatic group, a monocyclic aromatic group, a bieyelic aromatic group, a multicyclic aromatic group, a C₁₋₂₀ C₅₋₁₀ alicyclic group, a noncarbon/nonoxygen moiety, a carbohydrate, a lipid, a nucleic acid and a protein, and $m \le 4$ 30, and wherein any one of R₆, R₇, R₈ and R₀ can be attached covalently or noncovalently to a polymer of synthetic or natural origin, wherein in Formula I, one of R₆ and R₇ and one of R₈ and R₉ can be absent such that a double bond joins the two carbon atoms to which the remaining R groups are attached, wherein n = 0-420 in Formula I, and n = 1-20 in Formula II, wherein X is a heteroatom, and wherein R₁₀ and R₁₁ are independently selected from the group consisting of a C_{1-20} C_{1-6} aliphatic group, a monocyclic aromatic group, a bicyclic aromatic group, a multicyclic aromatic group, a C₁₋₂₀ aliphatic/aromatic group, a heteroatomic group, a C_{1-20} C_{1-6} ether-containing group, a C_{1-20} C_{3-6} keto group, a C_{1-20} C_{1-6} aldehydic group, a carboxamido group, a cyano group, an amino group, and a carboxyl group, a seleniumcontaining group, a sulfato group, a sulfito group, a sulfenato group, a sulfinato group, and a sulfonato group, and wherein R₁₀ and R₁₁ can be connected through an aliphatic group and/or an aromatic group, or R_{Id} and/or R_{II} can comprise a member selected from the group consisting of a carbohydrate, a lipid, a nucleic acid and a protein.

29. (Canceled)

30. (Currently Amended) A method for the prophylactic treatment of cancer delaying the onset of tumor formation in an animal, which method comprises administering to an

animal at risk for developing a cancer a nitroxide compound of Formula I or a prodrug thereof in an amount sufficient to delay the onset of tumor formation prevent said cancer, wherein said cancer tumor is susceptible to prevention by said nitroxide compound of Formula I or prodrug thereof, and wherein said nitroxide or prodrug thereof is a compound of Formula I is defined as or II:

Formula I or Formula II

wherein R_1 is selected from the group consisting of H, OH, OZ, O·, and =O-and Y, wherein Y is a leaving group, which can be converted to H, OH, O· or =O by reaction with a nucleophilic agent, and Z is selected from the group consisting of a C_{1-20} C_{1-6} aliphatic group, a monocyclic aromatic group, a bicyclic aromatic group, a multicyclic aromatic group, a C_{3-10} alicyclic group, a noncarbon/nonoxygen moiety, a carbohydrate, a lipid, a nucleic acid and a protein, wherein R_2 , R_3 , R_4 and R_5 are independently selected from the group consisting of a C_{1-20} C_{1-6} alkyl group, a C_{2-20} C_{2-6} alkenyl group, a C_{2-20} C_{2-6} alkynyl group, and -CH₂-[CR' R"]_m-CH₃, wherein R' is selected from the group consisting of hydrogen, a C_{1-20} C_{1-6} aliphatic group, and a monocyclic aromatic group, a bicyclic aromatic group, and a multicyclic aromatic group, a bicyclic aromatic group, a multicyclic aromatic group, a C_{1-20} C_{1-6} aliphatic group, a monocyclic aromatic group, a bicyclic aromatic group, a multicyclic aromatic group, a C_{1-20} C_{1-6} aliphatic group, a monocyclic aromatic group, a bicyclic aromatic group, a multicyclic aromatic group, a noncarbon/nonoxygen moiety, a carbohydrate, a lipid, a nucleic acid, and a protein,

m \leq 4 30, and R₂ and R₃ or R₄ and R₅ can be connected through one or more members, each of which is independently selected from the group consisting of carbon and a heteroatom, wherein R₆, R₇, R₈ and R₉ are independently selected from the group consisting of hydrogen, a hydroxyl group, a C₁₋₂₀ C₁₋₆ aldehydic group, a C₁₋₂₀ C₃₋₆ keto group, a primary amino group, a secondary amino group, a tertiary amino group, a sulfido group, a disulfido group, a sulfato group, a halide, a C₁₋₂₀ C₁₋₆ ester-containing group, a carboxyl group, a phosphino group, a phosphino group, a phosphino group, a phosphinato group, a phosphonato group, a C₁₋₂₀ C₁₋₆ alkyl group, a C₂₋₂₀ C₂₋₆ alkenyl group,

a C₂₋₂₀ C₂₋₆ alkynyl group, and -CH₂-[CR' R"]_m-CH₃, wherein R' is selected from the group consisting of hydrogen, a C_{1-20} C_{1-6} aliphatic group, and a monocyclic aromatic group, a bicyclic aromatic group, and a multicyclic aromatic group, and R" is selected from the group consisting of hydrogen, a C_{1-20} C_{1-6} aliphatic group, a monocyclic aromatic group, a bicyclic aromatic group, a multicyclic aromatic group, a C₁₋₂₀ C₅₋₁₀ alicyclic group, a noncarbon/nonexygen moiety, a carbohydrate, a lipid, a nucleic acid and a protein, and $m \le \underline{4}$ 30, and wherein any one of R₆, R₇, R₈ and R₉ can be attached covalently or noncovalently to a polymer of synthetic or natural origin, wherein in Formula I, one of R₆ and R₇ and one of R₈ and R₉ can be absent such that a double bond joins the two carbon atoms to which the remaining R groups are attached, wherein n = 0-4 20 in Formula I, and n = 1-20 in Formula II, wherein X is a heteroatom, and wherein R₁₀ and R₁₁ are independently selected from the group consisting of a C_{1-20} C_{1-6} aliphatic group, a monocyclic aromatic group, a bicyclic aromatic group, a multicyclic aromatic group, a C₁₋₂₀ aliphatic/aromatic group, a heteroatomic group, a C_{1-20} C_{1-6} ether-containing group, a C_{1-20} C_{3-6} keto group, a C_{1-20} C_{1-6} aldehydic group, a carboxamido group, a cyano group, an amino group, and a carboxyl group, a selenium-containing group, a sulfato group, a sulfato group, a sulfato group, a sulfinato group, and a sulfonato group, and wherein R₁₀ and R₁₁ can be connected through an aliphatic group and/or an aromatic group, or R₁₀ and/or R₁₁ can comprise a member selected from the group consisting of a carbohydrate, a lipid, a nucleic acid and a protein.

- 31. (Withdrawn) The method of claim 30, wherein said aliphatic group is branched, substituted and/or unsaturated.
- 32. (Withdrawn) The method of claim 31, wherein said aliphatic group is substituted with a member selected from the group consisting of oxygen, phosphorus, selenium, sulfur and nitrogen.
- 33. (Withdrawn) The method of claim 30, wherein said aromatic group comprises a five- or six-membered ring, in which each of the five or six members is independently selected from the group consisting of carbon and a heteroatom.
- 34. (Withdrawn) The method of claim 33, wherein said heteroatom is selected from the group consisting of nitrogen, oxygen, sulfur, phosphorus and boron.
 - 35. (Canceled)
 - 36. (Withdrawn) The method of claim 33, wherein said aromatic group is substituted.

- 37. (Withdrawn) The method of claim 36, wherein said aromatic group is substituted with a heteroatom.
- 38. (Withdrawn) The method of claim 37, wherein said heteroatom is selected from the group consisting of nitrogen, oxygen, sulfur, phosphorus and boron.
- 39. (Withdrawn) The method of claim 30, wherein said alicyclic group is substituted and/or unsaturated.
- 40. (Withdrawn) The method of claim 38, wherein said alicyclic group is substituted with a heteroatom.
 - 41. (Withdrawn) The method of claim 30, wherein said amino group is substituted.
- 42. (Withdrawn) The method of claim 41, wherein said amino group is substituted with up to three substituents selected from the group consisting of a C_{1-20} aliphatic group, a monocyclic aromatic group, a bicyclic aromatic group, a multicyclic aromatic group, and a C_{1-20} alicyclic group.
- 43. (Withdrawn) The method of claim 42, wherein said aromatic group comprises a five- or six-membered ring, in which each of the five or six members is independently selected from the group consisting of carbon and a heteroatom.
- 44. (Withdrawn) The method of claim 43, wherein said heteroatom is selected from the group consisting of nitrogen, oxygen, sulfur, phosphorus and boron.
 - 45. (Withdrawn) The method of claim 42, wherein said aromatic group is substituted.
- 46. (Withdrawn) The method of claim 45, wherein said aromatic group is substituted with a heteroatom.
- 47. (Withdrawn) The method of claim 46, wherein said heteroatom is selected from the group consisting of nitrogen, oxygen, sulfur, phosphorus and boron.
 - 48. (Canceled)

49. (Previously Presented) The method of claim 30, wherein the eancer tumor is caused by a genetic defect in the p53 gene.